Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

June 06, 2017; 88 (23) Article

Placebo and nocebo responses in restless legs syndrome

A systematic review and meta-analysis

Maria A. Silva, Gonçalo S. Duarte, Raquel Camara, Filipe B. Rodrigues, Ricardo M. Fernandes, Daisy Abreu, Tiago Mestre, João Costa, Claudia Trenkwalder, Joaquim J. Ferreira
First published May 10, 2017, DOI: https://doi.org/10.1212/WNL.0000000000004004
Maria A. Silva
From the Laboratory of Clinical Pharmacology and Therapeutics (M.A.S., G.S.D., R.C., F.B.R., R.M.F., D.A., J.C., J.J.F.), Portuguese Collaborating Center of the IberoAmerican Cochrane Network, Cochrane Portugal (G.S.D., R.M.F., J.C.), and Center for Evidence-Based Medicine (J.C.), Faculty of Medicine, University of Lisbon; Clinical Pharmacology Unit (M.A.S., G.S.D., R.C., F.B.R., R.M.F., D.A., J.C., J.J.F.), Instituto de Medicina Molecular, Lisbon, Portugal; Huntington's Disease Centre (F.B.R.), Institute of Neurology, University College London, UK; Parkinson's Disease and Movement Disorders Center (T.M.), Division of Neurology, Department of Medicine, The Ottawa Hospital Research Institute, University of Ottawa, Canada; Paracelsus-Elena Klinik (C.T.), Center of Parkinsonism and Movement Disorders, Kassel; and the Department of Neurosurgery (C.T.), University Medical Center, Göttingen, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gonçalo S. Duarte
From the Laboratory of Clinical Pharmacology and Therapeutics (M.A.S., G.S.D., R.C., F.B.R., R.M.F., D.A., J.C., J.J.F.), Portuguese Collaborating Center of the IberoAmerican Cochrane Network, Cochrane Portugal (G.S.D., R.M.F., J.C.), and Center for Evidence-Based Medicine (J.C.), Faculty of Medicine, University of Lisbon; Clinical Pharmacology Unit (M.A.S., G.S.D., R.C., F.B.R., R.M.F., D.A., J.C., J.J.F.), Instituto de Medicina Molecular, Lisbon, Portugal; Huntington's Disease Centre (F.B.R.), Institute of Neurology, University College London, UK; Parkinson's Disease and Movement Disorders Center (T.M.), Division of Neurology, Department of Medicine, The Ottawa Hospital Research Institute, University of Ottawa, Canada; Paracelsus-Elena Klinik (C.T.), Center of Parkinsonism and Movement Disorders, Kassel; and the Department of Neurosurgery (C.T.), University Medical Center, Göttingen, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Raquel Camara
From the Laboratory of Clinical Pharmacology and Therapeutics (M.A.S., G.S.D., R.C., F.B.R., R.M.F., D.A., J.C., J.J.F.), Portuguese Collaborating Center of the IberoAmerican Cochrane Network, Cochrane Portugal (G.S.D., R.M.F., J.C.), and Center for Evidence-Based Medicine (J.C.), Faculty of Medicine, University of Lisbon; Clinical Pharmacology Unit (M.A.S., G.S.D., R.C., F.B.R., R.M.F., D.A., J.C., J.J.F.), Instituto de Medicina Molecular, Lisbon, Portugal; Huntington's Disease Centre (F.B.R.), Institute of Neurology, University College London, UK; Parkinson's Disease and Movement Disorders Center (T.M.), Division of Neurology, Department of Medicine, The Ottawa Hospital Research Institute, University of Ottawa, Canada; Paracelsus-Elena Klinik (C.T.), Center of Parkinsonism and Movement Disorders, Kassel; and the Department of Neurosurgery (C.T.), University Medical Center, Göttingen, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Filipe B. Rodrigues
From the Laboratory of Clinical Pharmacology and Therapeutics (M.A.S., G.S.D., R.C., F.B.R., R.M.F., D.A., J.C., J.J.F.), Portuguese Collaborating Center of the IberoAmerican Cochrane Network, Cochrane Portugal (G.S.D., R.M.F., J.C.), and Center for Evidence-Based Medicine (J.C.), Faculty of Medicine, University of Lisbon; Clinical Pharmacology Unit (M.A.S., G.S.D., R.C., F.B.R., R.M.F., D.A., J.C., J.J.F.), Instituto de Medicina Molecular, Lisbon, Portugal; Huntington's Disease Centre (F.B.R.), Institute of Neurology, University College London, UK; Parkinson's Disease and Movement Disorders Center (T.M.), Division of Neurology, Department of Medicine, The Ottawa Hospital Research Institute, University of Ottawa, Canada; Paracelsus-Elena Klinik (C.T.), Center of Parkinsonism and Movement Disorders, Kassel; and the Department of Neurosurgery (C.T.), University Medical Center, Göttingen, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ricardo M. Fernandes
From the Laboratory of Clinical Pharmacology and Therapeutics (M.A.S., G.S.D., R.C., F.B.R., R.M.F., D.A., J.C., J.J.F.), Portuguese Collaborating Center of the IberoAmerican Cochrane Network, Cochrane Portugal (G.S.D., R.M.F., J.C.), and Center for Evidence-Based Medicine (J.C.), Faculty of Medicine, University of Lisbon; Clinical Pharmacology Unit (M.A.S., G.S.D., R.C., F.B.R., R.M.F., D.A., J.C., J.J.F.), Instituto de Medicina Molecular, Lisbon, Portugal; Huntington's Disease Centre (F.B.R.), Institute of Neurology, University College London, UK; Parkinson's Disease and Movement Disorders Center (T.M.), Division of Neurology, Department of Medicine, The Ottawa Hospital Research Institute, University of Ottawa, Canada; Paracelsus-Elena Klinik (C.T.), Center of Parkinsonism and Movement Disorders, Kassel; and the Department of Neurosurgery (C.T.), University Medical Center, Göttingen, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daisy Abreu
From the Laboratory of Clinical Pharmacology and Therapeutics (M.A.S., G.S.D., R.C., F.B.R., R.M.F., D.A., J.C., J.J.F.), Portuguese Collaborating Center of the IberoAmerican Cochrane Network, Cochrane Portugal (G.S.D., R.M.F., J.C.), and Center for Evidence-Based Medicine (J.C.), Faculty of Medicine, University of Lisbon; Clinical Pharmacology Unit (M.A.S., G.S.D., R.C., F.B.R., R.M.F., D.A., J.C., J.J.F.), Instituto de Medicina Molecular, Lisbon, Portugal; Huntington's Disease Centre (F.B.R.), Institute of Neurology, University College London, UK; Parkinson's Disease and Movement Disorders Center (T.M.), Division of Neurology, Department of Medicine, The Ottawa Hospital Research Institute, University of Ottawa, Canada; Paracelsus-Elena Klinik (C.T.), Center of Parkinsonism and Movement Disorders, Kassel; and the Department of Neurosurgery (C.T.), University Medical Center, Göttingen, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tiago Mestre
From the Laboratory of Clinical Pharmacology and Therapeutics (M.A.S., G.S.D., R.C., F.B.R., R.M.F., D.A., J.C., J.J.F.), Portuguese Collaborating Center of the IberoAmerican Cochrane Network, Cochrane Portugal (G.S.D., R.M.F., J.C.), and Center for Evidence-Based Medicine (J.C.), Faculty of Medicine, University of Lisbon; Clinical Pharmacology Unit (M.A.S., G.S.D., R.C., F.B.R., R.M.F., D.A., J.C., J.J.F.), Instituto de Medicina Molecular, Lisbon, Portugal; Huntington's Disease Centre (F.B.R.), Institute of Neurology, University College London, UK; Parkinson's Disease and Movement Disorders Center (T.M.), Division of Neurology, Department of Medicine, The Ottawa Hospital Research Institute, University of Ottawa, Canada; Paracelsus-Elena Klinik (C.T.), Center of Parkinsonism and Movement Disorders, Kassel; and the Department of Neurosurgery (C.T.), University Medical Center, Göttingen, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
João Costa
From the Laboratory of Clinical Pharmacology and Therapeutics (M.A.S., G.S.D., R.C., F.B.R., R.M.F., D.A., J.C., J.J.F.), Portuguese Collaborating Center of the IberoAmerican Cochrane Network, Cochrane Portugal (G.S.D., R.M.F., J.C.), and Center for Evidence-Based Medicine (J.C.), Faculty of Medicine, University of Lisbon; Clinical Pharmacology Unit (M.A.S., G.S.D., R.C., F.B.R., R.M.F., D.A., J.C., J.J.F.), Instituto de Medicina Molecular, Lisbon, Portugal; Huntington's Disease Centre (F.B.R.), Institute of Neurology, University College London, UK; Parkinson's Disease and Movement Disorders Center (T.M.), Division of Neurology, Department of Medicine, The Ottawa Hospital Research Institute, University of Ottawa, Canada; Paracelsus-Elena Klinik (C.T.), Center of Parkinsonism and Movement Disorders, Kassel; and the Department of Neurosurgery (C.T.), University Medical Center, Göttingen, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Claudia Trenkwalder
From the Laboratory of Clinical Pharmacology and Therapeutics (M.A.S., G.S.D., R.C., F.B.R., R.M.F., D.A., J.C., J.J.F.), Portuguese Collaborating Center of the IberoAmerican Cochrane Network, Cochrane Portugal (G.S.D., R.M.F., J.C.), and Center for Evidence-Based Medicine (J.C.), Faculty of Medicine, University of Lisbon; Clinical Pharmacology Unit (M.A.S., G.S.D., R.C., F.B.R., R.M.F., D.A., J.C., J.J.F.), Instituto de Medicina Molecular, Lisbon, Portugal; Huntington's Disease Centre (F.B.R.), Institute of Neurology, University College London, UK; Parkinson's Disease and Movement Disorders Center (T.M.), Division of Neurology, Department of Medicine, The Ottawa Hospital Research Institute, University of Ottawa, Canada; Paracelsus-Elena Klinik (C.T.), Center of Parkinsonism and Movement Disorders, Kassel; and the Department of Neurosurgery (C.T.), University Medical Center, Göttingen, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joaquim J. Ferreira
From the Laboratory of Clinical Pharmacology and Therapeutics (M.A.S., G.S.D., R.C., F.B.R., R.M.F., D.A., J.C., J.J.F.), Portuguese Collaborating Center of the IberoAmerican Cochrane Network, Cochrane Portugal (G.S.D., R.M.F., J.C.), and Center for Evidence-Based Medicine (J.C.), Faculty of Medicine, University of Lisbon; Clinical Pharmacology Unit (M.A.S., G.S.D., R.C., F.B.R., R.M.F., D.A., J.C., J.J.F.), Instituto de Medicina Molecular, Lisbon, Portugal; Huntington's Disease Centre (F.B.R.), Institute of Neurology, University College London, UK; Parkinson's Disease and Movement Disorders Center (T.M.), Division of Neurology, Department of Medicine, The Ottawa Hospital Research Institute, University of Ottawa, Canada; Paracelsus-Elena Klinik (C.T.), Center of Parkinsonism and Movement Disorders, Kassel; and the Department of Neurosurgery (C.T.), University Medical Center, Göttingen, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
Placebo and nocebo responses in restless legs syndrome
A systematic review and meta-analysis
Maria A. Silva, Gonçalo S. Duarte, Raquel Camara, Filipe B. Rodrigues, Ricardo M. Fernandes, Daisy Abreu, Tiago Mestre, João Costa, Claudia Trenkwalder, Joaquim J. Ferreira
Neurology Jun 2017, 88 (23) 2216-2224; DOI: 10.1212/WNL.0000000000004004

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
214

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

Abstract

Objective: To estimate the placebo and nocebo responses in restless legs syndrome (RLS) and explore their determinants.

Methods: Databases were searched up to October 2015. Randomized, double-blind, placebo-controlled trials of patients with RLS were included if quantitative data were extractable in the placebo arm. Placebo response was defined as the within-group change from baseline, using any scale measuring RLS severity or disability. Nocebo response was defined as the proportion of patients experiencing adverse events in the placebo arm. Random-effects meta-analysis was used to pool data. Statistical heterogeneity was assessed with I2 statistic. Several predetermined subgroup and sensitivity analysis were performed. PROSPERO registration number is CRD42015027992.

Results: We included 85 randomized controlled trials (5,046 participants). Pooled placebo response effect size was −1.41 (95% confidence interval [CI] −1.56 to −1.25, 64 trials, I2 = 88.1%), corresponding to −6.58 points in the International RLS Study Group Scale (IRLS). Pooled nocebo response was 45.36% (95% CI 40.47%–50.29%, 72 trials; I2 = 89.8%). The placebo and nocebo responses were greater in trials with longer duration, evaluating pharmacologic interventions and idiopathic RLS, and in industry-funded and unpublished studies. The placebo response was considerably smaller in objective as compared to subjective outcomes. In addition, the nocebo response increases proportionally with the placebo response, and has the same predictors.

Conclusions: The magnitude of the placebo response in RLS is above the threshold of minimal clinical important difference, and the frequency of adverse events is also considerable. These results are relevant to inform the design and interpretation of future clinical trials.

GLOSSARY

CGI=
Clinical Global Impression improvement scale;
CI=
confidence interval;
ES=
effect size;
IRLSSG=
International RLS Study Group;
MCID=
minimal clinically important difference;
PGI=
Patient Global Impression improvement scale;
PLM=
periodic limb movements;
PLMI=
periodic limb movements index;
PLMSI=
periodic limb movements of sleep index;
RCT=
randomized controlled trial;
RLS=
restless legs syndrome

Footnotes

  • Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

  • Supplemental data at Neurology.org

  • Editorial, page 2160

  • Received October 3, 2016.
  • Accepted in final form February 28, 2017.
  • © 2017 American Academy of Neurology
View Full Text

AAN Members

We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.

Google Safari Microsoft Edge Firefox

Click here to login

AAN Non-Member Subscribers

Click here to login

Purchase access

For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)

Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here 

Purchase
Individual access to articles is available through the Add to Cart option on the article page.  Access for 1 day (from the computer you are currently using) is US$ 39.00.  Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means.  The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use.  Distributing copies (electronic or otherwise) of the article is not allowed.

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Abstract
    • GLOSSARY
    • METHODS
    • RESULTS
    • DISCUSSION
    • AUTHOR CONTRIBUTIONS
    • STUDY FUNDING
    • DISCLOSURE
    • ACKNOWLEDGMENT
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Disclosures
Advertisement

Related Articles

  • Restless legs syndromeLosing sleep over the placebo response

Topics Discussed

  • Clinical trials Systematic review/meta analysis
  • Restless legs syndrome

Alert Me

  • Alert me when eletters are published
Neurology: 96 (8)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2021 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise